Acelyrin, Inc. reported a net loss of $55.264 million for the three months ended March 31, 2025, compared to a net loss of $34.973 million for the same period in 2024. The loss from operations was $59.855 million. The company continues to incur significant expenses related to research and development, with no product revenue generated to date.

Acelyrin's financial performance in Q4 2024 showed a significant reduction in net loss and total operating expenses compared to the previous year, primarily due to lower license fees and acquired in-process research and development expenses. The company also saw a notable increase in interest income and other income, contributing to the improved financial position.

ACELYRIN reported their Q3 2024 financial results, highlighting a cash position of $562.4 million, which is projected to fund operations until mid-2027. They also completed a positive end of Phase 2 interaction with the FDA for lonigutamab and anticipate initiating a subcutaneous Phase 3 development program in thyroid eye disease (TED) in Q1 2025. Topline data from the Phase 2b/3 trial of izokibep for uveitis is expected in December 2024.

Acelyrin announced positive Phase 3 data for Izokibep in Hidradenitis Suppurativa, met primary endpoint of HiSCR75 at 12 weeks. The company will prioritize the development of Lonigutamab and expects to initiate a Phase 3 program in Q1 2025. Cash, cash equivalents, and short-term marketable securities totaled $635.2 million at June 30, 2024, which is projected to extend the cash runway to mid-2027.

Acelyrin reported its cash, cash equivalents, and short-term marketable securities totaled $678.5 million as of March 31, 2024. Additionally, Mina Kim was appointed as the Chief Executive Officer, succeeding Shao-Lee Lin, and Ron Oyston will step down as Chief People Officer effective August 15, 2024.

ACELYRIN reported its Q2 2023 financial results, highlighting clinical and corporate milestones, including new data from the Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa and the completion of enrollment in the Phase 2b/3 trial of izokibep in Psoriatic Arthritis. The company's strong cash position of $823.0 million, including gross proceeds from a recent IPO of $621.0 million, is expected to support multiple late-stage clinical programs.

ACELYRIN reported a net loss of $176.5 million for Q1 2023, including a one-time $123.1 million IPR&D charge and $10.0 million license payment related to the ValenzaBio acquisition. The company's cash and cash equivalents totaled $289.2 million at the end of the quarter, with expectations to fund operations through key milestones using IPO proceeds and existing cash.